According to research report the dPCR qPCR market
is projected to reach USD 6.3 billion by 2024 from USD 4.1 billion in
2019. The market is expected to grow at a CAGR of 8.8% from 2019 to
2024.
Ask For Free PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204
The
growth of the market is primarily driven by the rising incidences of
target infectious diseases and genetic disorders, increasing financial
support for research, and the increasing use of biomarker profiling in
disease diagnostics. Companies in the digital PCR market are focusing on
novel product development (including lab-on-chip devices, miniaturized
devices, and microfluidics-based instruments) to cater to the growing
end-user demand for technologically advanced dPCR and qPCR products.
North
America accounted for the largest share of the digital PCR q PCR market
in 2019, followed by Europe. The large share of North American dPCR
qPCR market is mainly due to the rising number of genome-based drug
development activities undertaken by US-based pharmaceutical and
biotechnology companies, increasing support for the development of dPCR
and qPCR technologies, a growing target patient base, and the focus on
early and effective disease diagnosis.
The hospitals and
diagnostic centres segment is expected to dominate the qPCR market in
2019. The large share of this segment is attributed to the increasing
market availability of qPCR reagents in clinical diagnostic
applications; ongoing expansion of healthcare infrastructure across
emerging countries; high prevalence & incidence of target diseases;
and growing awareness on the benefits of qPCR.
The global dPCR
and qPCR market offers significant growth potential for current and
future players. The digital PCR market is consolidated in nature, with
leading players acquiring small market players to gain their
state-of-the-art PCR technologies and strengthen their market presence.
This also helps them to strengthen their R&D and distribution
network and penetrate markets in emerging nations.
The qPCR
reagents & consumables segment is expected to command the largest
share of the qPCR products & services market. Factors such as the
expanding applications of qPCR (owing to its technological benefits over
traditional PCR, such as real-time analysis and reduced analysis time),
growing private-public funding for life sciences research, and the
rising number of probe-based multiplex genetic analysis procedures (that
require the analysis of low-volume gene samples) are expected to drive
the growth of the qPCR reagents and consumables market.
The major players operating in the dPCR qPCR Market
are Thermo Fisher Scientific, Inc. (US), F. Hoffman-La Roche Ltd.
(Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Germany),
Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux
S.A. (France), Fluidigm Corporation (US), Danaher Corporation (US),
Abbott Laboratories (US), Merck KGaA (Germany), Becton Dickinson and
Company (US), Promega Corporation (US), Eppendorf AG (Germany), and
Analytik Jena AG (Germany).
Download Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174151204